Wutah pendapatan taun lumaku: Kintara Pharma (KTRA)

Kintara Therapeutics (KTRA) is developing anti-tumor agents through partnerships with medical centers and strategic M&A. The laboratory search for new formulas is accelerating through the implementation of robotic screening. The current year-over-year sales trend over 12 months demonstrates revenue dynamics, where 0.00 captures the current value of the indicator. A merger with a cell therapy platform helps the company diversify its clinical risks.
Kintara Therapeutics - rincian analitis lan metrik utama (KTRA)

This indicator measures the revenue growth rate over the last four quarters relative to the previous year, neutralizing seasonal fluctuations to identify the net direction of business development. For Kintara Therapeutics (KTRA), which focuses on developing therapies for rare oncological diseases, this metric reflects the commercial efficiency of its scientific activities, as clearly evidenced by the 12-month annual revenue trajectory.